STOCK TITAN

60 degrees pharmaceuticals, Inc. SEC Filings

SXTP NASDAQ

60 Degrees Pharmaceuticals filings document a specialty pharmaceutical issuer with Nasdaq-listed common stock and warrants, emerging-growth-company status and a business focused on medicines for vector-borne disease. Its recent Form 8-K disclosures record material events involving the company’s at-the-market equity offering program, related legal opinions, beneficial-ownership corrections, investor-presentation materials, and clinical development and regulatory strategy updates.

The filing record also covers capital-structure and governance matters, including a one-for-four reverse stock split approved through amendments to the certificate of incorporation, annual meeting voting results and Nasdaq listing-compliance notices. These disclosures frame the company’s formal reporting around ARAKODA, tafenoquine development, equity financing mechanics, security-holder votes and exchange-related requirements.

Rhea-AI Summary

60 Degrees Pharmaceuticals, Inc. filed an 8-K announcing proposals for its upcoming shareholder meeting. Shareholders will vote on electing directors, increasing the 2022 Equity Incentive Plan by 250,000 shares, and approving an amendment to the certificate of incorporation to permit a reverse stock split at a ratio between 1:3 and 1:10, to be set by the Board. The company also seeks ratification of RBSM LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025 and authorization to adjourn the meeting if additional proxy solicitation is needed. The filing lists these discrete corporate governance proposals without additional financial detail.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Geoffrey S. Dow, President and CEO and a director of 60 Degrees Pharmaceuticals, Inc. (SXTP), reported an open-market purchase of company common stock on September 12, 2025. He acquired 7,201 shares at a reported price of $1.3881 per share. Following the transaction, Mr. Dow directly beneficially owns 33,372 shares and indirectly beneficially owns 11,119 shares through the Geoffrey S. Dow Revocable Trust, of which he is trustee and retains voting and dispositive control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

How many 60 degrees pharmaceuticals (SXTP) SEC filings are available on StockTitan?

StockTitan tracks 22 SEC filings for 60 degrees pharmaceuticals (SXTP), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for 60 degrees pharmaceuticals (SXTP)?

The most recent SEC filing for 60 degrees pharmaceuticals (SXTP) was filed on October 10, 2025.